A leakproof shipper is not laboratory-manual identity
When the scheduled visit kit is unavailable, a site may be offered a substitute: an auxiliary backup kit, a locally sourced evacuated tube, or a different shipping carton. The reader job is narrower than packing selection or post-collection data review. Reconcile protocol and laboratory-manual identity, and the preanalytical evidence those documents lock, before collection. Do not treat shipping compliance as proof that endpoint data remain comparable.
A common failure mode is equating physical shipping compliance with bioanalytical validity. An offered carton may arrive with a Category B mark or leakproof-packaging documentation. Adjacent packing-selection reading is MedConsumablesGuide's Category B specimen packaging guide—a publication page on Category B as a transport class versus a tube catalog, not this precollection identity worksheet. MedConsumablesGuide is a publication, not a central laboratory, kit vendor, regulator, sterilizer, or proof of specimen validity. Satisfying 49 CFR 173.199 containment rules does not establish that the primary receptacle, additive, processing step, or temperature profile matches the laboratory-manual identity used to support the endpoint assay.
Prospective precollection kit reconciliation addresses a fundamentally different question than retrospective operational investigations. When evaluating laboratory hardware failures after service, study teams perform time-bounded data reviews, as examined in assessing endpoint data after analyzer service. Similarly, when study participants experience background therapy disruptions due to billing or insurance disputes, trial teams establish contemporaneous exposure chronologies before statisticians classify intercurrent events, as outlined in mapping coverage gaps to trial treatment interruptions. Kit-substitution review occurs before a specimen is drawn. Once a sample is collected into an unmatched primary container, later analysis cannot recreate the unmatched preanalytical conditions. Same-estimand sensitivity analysis is a different job after an observation already exists; it is not a reconstruction of an unmatched tube.
This worksheet is also not the published ICH E6(R3) endpoint and eClinical implementation checklist, not risk-based validation of computerized systems that capture endpoints, and not estimand-aligned sensitivity analysis for missing data versus intercurrent events. Those pages answer different jobs. A substitute kit is a prospective identity question before collection, not a post-collection estimator and not a platform-qualification file.
What ICH M10 still requires of matrix, anticoagulant, and container—and what it does not cover
To judge a substitute kit against a locked method, start with ICH M10's scope—and its limits. On 24 May 2022, ICH finalized M10 Bioanalytical Method Validation and Study Sample Analysis at Step 4. FDA issued the same text as guidance for industry in November 2022; the FDA guidance landing page was current as of 12 June 2024 and states that it replaces the 27 June 2019 draft M10 guidance. M10 is a guideline and a set of nonbinding FDA recommendations. It is not a statute, not a kit-substitution permission, and not a rule for every laboratory endpoint.
ICH M10 applies to chromatographic methods and ligand-binding assays used to measure concentrations of chemical and biological drugs and their metabolites in biological samples obtained in GLP toxicokinetic studies, specified nonclinical pharmacokinetic studies conducted as surrogates for clinical studies, and all phases of clinical trials, including comparative bioavailability/bioequivalence studies. The bioanalysis of biomarkers and bioanalytical methods used to assess immunogenicity are not within the scope of M10. Do not treat M10 as a rule for every safety-laboratory, imaging, or COA endpoint.
Within that scope, ICH M10 states that the matrix used for bioanalytical method validation should be the same as the matrix of the study samples, including anticoagulants and additives. Surrogate matrices may be acceptable for rare matrices such as tissue, cerebrospinal fluid, or bile, or when free drug is measured, if the choice is scientifically justified. Matrix differences within species such as age, ethnicity, or sex are generally not considered different when validating a method. A catalog look-alike tube, a different additive, or an undocumented anticoagulant is therefore a matrix-identity field against the locked method, not a shipping-compliance finding. A change from heparin to EDTA is a typical chromatographic partial-validation modification; a change only in the counter-ion is listed as outside that typical list.
ICH M10 also states that stability evaluations should ensure that every step taken during sample preparation, processing, and analysis, as well as the storage conditions used, do not affect the concentration of the analyte. The storage and analytical conditions applied to the stability tests, such as the sample storage times and temperatures, sample matrix, anticoagulant, and container materials, should reflect those used for the study samples. Reference to data published in the literature is not considered sufficient. Validation of storage periods should use quality-control samples stored for a time equal to or longer than the study-sample storage periods. A substitute kit that changes container material, anticoagulant, processing, or storage or shipping temperature is therefore a precollection identity question against the validated conditions, not a number imported from a literature stability table.
When a fully validated bioanalytical method is modified, ICH M10 section 6.1 states that those modifications may be evaluated by partial validation. Partial validation can range from as little as one within-run accuracy and precision determination to a nearly full validation. The parameters of the partial validations should meet the full validation criteria. For chromatographic methods, typical modifications that fall into this category include, but are not limited to:
A change in anticoagulant (but not changes in the counter-ion) in biological fluids, such as heparin to ethylenediaminetetraacetic acid (EDTA);
A change in sample processing procedures;
A change in storage conditions;
A change from one matrix within a species to another, such as human plasma to serum.
That list is a laboratory-method modification category. It is not a finding that a site may collect into a substitute tube, not a shipping-compliance certificate, and not a universal requirement to run a bridging or cross-validation study before any kit change. Cross-validation is a separate M10 section 6.2 used when multiple methods or laboratories generate data that must be related. ICH M10 is a guideline, not a statute, and it does not convert a Category B mark into assay comparability.
Cite the May 2018 FDA Bioanalytical Method Validation guidance as that document's text: before initiating validation, the sponsor should establish a detailed written description of the bioanalytical method that identifies procedures controlling critical parameters, including environmental, matrix, and procedural variables, from the time of collection of the samples to the time of analysis. The same 2018 guidance listed a change in anticoagulant (but not the counter-ion), such as heparin to EDTA, among modifications evaluated by partial validation. FDA's April 2026 Bioanalytical Method Validation for Biomarkers guidance, content current as of 10 April 2026, states that M10 excludes biomarkers, that M10 was expected to supersede the 2018 guidance for measurement of drugs and biological products, and that upon publication of the biomarker guidance the May 2018 guidance will be withdrawn. The 2018 HTML landing page remained posted at research access with content current as of 29 April 2020. Treat November 2022 M10 as the current FDA-implemented ICH recommendation for chromatographic and ligand-binding drug and metabolite assays, and treat the April 2026 biomarker guidance as the current FDA biomarker-concentration document. Do not present 2018 as the sole current governing BMV for drug-concentration assays.
Chain of custody, investigator review, and CLIA client instructions where they actually apply
A substitute kit is also a collection-identity and chain-of-custody question before laboratory results are treated as the protocol endpoint. The ICH E6(R3) consolidated Step 4 guideline dated 16 June 2026 is a guideline, not a statute. Under section 2.12.2, the investigator/institution should maintain adequate source records that include pertinent observations on each trial participant. Source records should be attributable, legible, contemporaneous, original, accurate, and complete. Changes should be traceable, should not obscure the original entry, and should be explained if necessary via an audit trail.
Section 2.12.3 states that the investigator should be provided with timely access to data by the sponsor and should be responsible for the timely review of data, including relevant data from external sources that can have an impact on, for example, participant eligibility, treatment, or safety, including central laboratory data. Appendix C essential records for the sponsor include documents of the collection, chain of custody, processing, analysis, and retention or destruction of biological samples. A substitute kit that changes the collection container, additive, processing, or shipping condition is therefore a reconstructable-record question before those results are treated as the protocol endpoint. E6(R3) does not convert a Category B mark into assay comparability, and it does not tell a site to collect.
Where CLIA applies, 42 CFR 493.1242 (Standard: Specimen submission, handling, and referral; eCFR Title 42 last amended 13 August 2026) requires a laboratory that performs applicable nonwaived testing to establish and follow written policies and procedures, if applicable, for:
Patient preparation;
Specimen collection;
Specimen labeling, including patient name or unique patient identifier and, when appropriate, specimen source;
Specimen storage and preservation;
Conditions for specimen transportation;
Specimen processing;
Specimen acceptability and rejection; and
Specimen referral.
If the laboratory accepts a referral specimen, written instructions must be available to the laboratory's clients and must include, as appropriate, the information specified in 493.1242(a)(1) through (a)(7). Those client-instruction and acceptability rules are laboratory-manual identity where CLIA applies. They are not a Category B packing certificate, not proof that a substitute kit matches the locked manual, and not a federal command that every unmatched tube must be rejected. Record the destination laboratory's written instructions; do not invent them.
42 CFR 493.3 states that, except as specified in paragraph (b), a laboratory will be cited as out of compliance with PHS Act section 353 unless it has a current CLIA certificate of the applicable type or is CLIA-exempt. Paragraph (b)(2) excepts research laboratories that test human specimens but do not report patient-specific results for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, individual patients. Do not treat 42 CFR 493.1242 as applying to every bioanalytical laboratory. A pharmacokinetic or biomarker laboratory that does not report patient-specific clinical results may fall outside that CLIA duty while ICH M10 or the April 2026 biomarker guidance still speaks to method identity. A central safety laboratory that reports patient-specific results may be under 493.1242. Record which laboratory regime actually applies; do not invent it.
Category B packing fields versus assay identity
When an offered kit emphasizes dangerous-goods transport certification, separate that packing field from assay identity. In the United States, PHMSA's Hazardous Materials Regulations address biological-substance transportation in 49 CFR part 173. The Title 49 display used here is current as of 3 September 2026; eCFR is authoritative but unofficial.
Under 49 CFR 173.134(a)(1)(ii), a Category B infectious substance is an infectious substance that is not in a form generally capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals when exposure occurs, including Category B infectious substances transported for diagnostic or investigational purposes. A Category B infectious substance must be described as Biological substance, Category B and assigned identification number UN3373. Section 173.134(a)(5) is the separate definition of regulated medical waste, not the Category B definition. Materials listed in 173.134(b) are not subject to the hazardous-materials subchapter as Division 6.2 materials, including, at (b)(1), a material that does not contain an infectious substance or that is unlikely to cause disease in humans or animals. Section 173.134(b)(11) excepts specified human or animal samples transported for routine testing not related to diagnosis of an infectious disease, or for tests for diagnosis of non-infectious diseases, for which there is a low probability the sample is infectious.
Not every trial specimen is a Category B infectious substance, and not every specimen is UN3373. Dangerous-goods classification is a shipper and laboratory or sponsor decision. A site catalog substitution does not assign the class. Do not assign Category B, Category A, or excepted-specimen status from a catalog photo or from the fact that a trial collected a blood tube.
When a trial specimen is classified as Category B, 49 CFR 173.199 (source note last amended 26 July 2022) requires a triple packaging consisting of a primary receptacle, a secondary packaging, and a rigid outer packaging. For shipments by aircraft, 173.199(b)(4) requires that the primary receptacle or the secondary packaging must be capable of withstanding without leakage an internal pressure producing a pressure differential of not less than 95 kPa (0.95 bar, 14 psi). Those packing rules address containment during transport, as discussed in adjacent packing-selection reading at MedConsumablesGuide's guide to UN3373 packaging systems. Satisfying the 95 kPa aircraft test does not establish that a substitute tube, additive, processing step, or temperature profile matches the laboratory manual used to support the endpoint assay. A Category B mark or a leakproof shipper is a transport-compliance field, not assay comparability.
Prospective substitution checklist and labeled fictional offers
Use a structured precollection reconciliation worksheet. Capture seven fields for every offered kit modification before any biological specimen is obtained:
Specimen or Matrix: The exact biological fluid, tissue, or cell preparation named in the protocol or laboratory manual, or an explicit unknown.
Offered vs. Locked Collection Component: The physical container, additive or anticoagulant, swab or media, shipper, and temperature profile offered versus locked.
Laboratory-Manual Identity & Version: The laboratory-manual identity and version, or an explicit unknown.
Specification Source: Locked manual, M10 method description, CLIA client instructions if CLIA applies, 173.199 packing if Category B applies, or unknown.
Endpoint Dependency: Chromatographic or ligand-binding drug/metabolite assay under M10, biomarker under the April 2026 guidance, CLIA-reported safety result, or unknown.
Unknown Compatibility: What still cannot be shown to match the locked identity.
Decision Owner: The sponsor or laboratory decision owner who may accept, reject, or require further method work before collection.
The following matrix applies the worksheet to four labeled hypothetical substitution offers. The rows are internally consistent fictions. They are not an actual kit, laboratory clearance, bridging study, or permission to substitute.
| Specimen / Matrix | Offered vs. Locked Component | Lab Manual Identity & Version | Specification Source | Endpoint Dependency | Unknown Compatibility | Decision Owner |
|---|---|---|---|---|---|---|
| Hypothetical A: Human plasma, as named in the locked laboratory manual | Offered K2-EDTA tube versus locked sodium heparin tube | Laboratory manual v2.1, locked | ICH M10 section 6.1 (chromatographic anticoagulant change is a typical partial-validation modification) | Chromatographic pharmacokinetic drug-concentration endpoint (AUC, Cmax) | Anticoagulant class (heparin to EDTA) has not been shown to match the locked validation matrix; partial-validation status unknown | Sponsor bioanalytical method owner and receiving PK laboratory |
| Hypothetical B: Human serum, as named in the locked safety-laboratory manual | Offered Category B-marked leakproof shipper whose primary receptacle is a glass clot-activator tube versus locked plastic serum-separator tube | Laboratory manual v3.0, locked | 49 CFR 173.199 packing if Category B applies; 42 CFR 493.1242 client instructions if CLIA applies | CLIA-reported safety chemistry (ALT, AST, total bilirubin), where the receiving laboratory reports patient-specific results | Shipper may satisfy 173.199 containment; primary receptacle still unmatched to the locked manual. Packing mark is not assay identity | Receiving safety-laboratory director and sponsor clinical operations lead |
| Hypothetical C: Human serum, offered as a catalog-matched evacuated tube | Offered catalog-matched evacuated tube versus locked study-specific tube; lot and surfactant unknown | Laboratory-manual version explicitly unknown | FDA April 2026 biomarker guidance (M10 does not govern biomarkers) | Biomarker concentration endpoint under the April 2026 guidance; named cytokines are illustrative only | Catalog dimensions match; locked manual version, lot, and container materials remain unknown. Catalog match is not locked identity | Sponsor biomarker assay owner; do not collect on an unknown manual version |
| Hypothetical D: Specimen/matrix named in the offer is unknown | Offered unmarked auxiliary shipper versus locked visit kit; primary receptacle additive not documented on the offer | Laboratory-manual version unknown | Unknown whether 49 CFR 173.134 Category B/UN3373 applies; unknown whether 42 CFR 493.1242 client instructions apply | Unknown whether the draw supports an M10 drug/metabolite assay, a biomarker under the April 2026 guidance, or a CLIA-reported safety result | Whether the specimen is Category B/UN3373 is unknown; whether CLIA client instructions apply is unknown; offered versus locked identity is unknown | Sponsor laboratory-manual owner and receiving-laboratory scientific director; do not collect and do not assign a shipping class |
Analyzing these four hypothetical offers reveals critical decision rules:
In Hypothetical A, the site is offered an EDTA tube when the locked chromatographic pharmacokinetic method specifies heparin. ICH M10 section 6.1 lists a change in anticoagulant (but not the counter-ion), such as heparin to EDTA, as a typical modification evaluated by partial validation. That is a laboratory-method question, not a shipping-compliance finding and not site permission to collect. Escalate to the sponsor bioanalytical method owner before collection. Do not invent a numeric stability limit or treat partial validation as a universal bridging-study mandate.
In Hypothetical B, the offered shipper is Category B-marked and described as leakproof. Those are 49 CFR 173.199 containment fields if Category B actually applies. The primary receptacle still does not match the locked laboratory manual. A Category B mark does not prove assay identity, and 42 CFR 493.1242 does not convert the mark into comparability or command automatic rejection of every unmatched tube. Record the unmatched primary receptacle and escalate to the receiving laboratory before collection.
In Hypothetical C, the offered tube is catalog-matched, but the laboratory-manual version is unknown. A catalog match is not locked identity. The April 2026 biomarker guidance excludes this draw from M10's drug-assay scope; it does not invent lot-specific validation as a universal essential and does not authorize collection. Leave the unknown manual version unknown and escalate to the biomarker assay owner.
In Hypothetical D, both the Category B/UN3373 class and CLIA client-instruction applicability remain unknown, and the offered versus locked identity is not documented. Do not assign Category B, Category A, or excepted-specimen status from the offer packet. Do not apply 42 CFR 493.1242 as a universal bioanalytical-lab rule. Leave those fields unknown, postpone collection, and send the worksheet to the sponsor laboratory-manual owner.
Operational escalation workflow before collection
When an unmatched collection or shipping kit is offered, use the worksheet before collection. The following diagram is an operational handoff, not a statute and not permission to collect:
flowchart TD
A["Substitute collection or shipping kit offered"] --> B{"Offered component matches locked laboratory-manual identity and version?"}
B -- Yes --> C["Collect under the locked manual"]
B -- No or unknown --> D["Set the offer aside"]
D --> E["Record offered versus locked fields on the worksheet"]
E --> F{"Endpoint dependency"}
F --> G["M10 chromatographic or LBA drug/metabolite assay"]
F --> H["CLIA-reported safety result if CLIA applies"]
F --> I["Category B packing if that class applies"]
F --> U["Unknown dependency"]
G --> J{"Anticoagulant, matrix, container, processing, or storage differs?"}
J -- Typical M10 partial-validation modification --> K["Escalate to bioanalytical method owner before collection"]
J -- Unknown --> K
J -- No documented difference --> P
H --> M["Compare with 42 CFR 493.1242 client instructions if CLIA applies"]
I --> N["173.199 is containment, not assay identity"]
U --> P
K --> P
M --> P
N --> P
P{"Decision owner accepts, rejects, or requires method work?"}
P -- Accepts in writing --> Q["Record actual component identity in source records"]
P -- Rejects or unanswered --> R["Postpone collection; do not assign a shipping class"]The worksheet can be run as four operational stages. None of these stages is a protocol-deviation classification, a bridging-study mandate, or site permission to collect:
Stage 1: Set the offer aside and compare identity. Set the unmatched offer aside. Compare the offered container, additive, shipper, and temperature profile against the locked laboratory manual. Record unknowns as unknowns.
Stage 2: Version and Specification Reconciliation. Match the offer to the locked laboratory-manual version, or record that the version is unknown. A catalog look-alike is not a version match.
Stage 3: Regulatory and Analytical Scope Mapping. Record whether the endpoint is an M10 chromatographic or ligand-binding drug/metabolite assay, a biomarker under the April 2026 guidance, a CLIA-reported safety result, or unknown. Record whether 173.199 packing applies only if Category B applies. Transport certification does not resolve assay identity.
Stage 4: Formal Escalation and Contemporaneous Source Recording. Send the completed worksheet to the named sponsor or laboratory decision owner. If that owner accepts the offer after method work that the owner specifies, record the written decision and the actual collection-component identity in source records under E6(R3) 2.12. If the owner rejects the offer or the fields remain unknown, postpone collection. Do not collect on an unknown, and do not overwrite the laboratory manual to fit the offer.
A Category B mark, a leakproof shipper, or a catalog-matched tube is a transport or catalog field. It is not laboratory-manual identity and not proof that endpoint data remain comparable. Reconcile the seven worksheet fields before collection. Do not invent substitution rates, stability limits, shipping class, or a universal bridging study, and do not treat MedConsumablesGuide's Category B packing page as this trial identity worksheet.